Screen · Berkshire Criteria

Buffett Quality Screen

Buffett's "wonderful business" criteria, quantified into six dimensions: earnings record (20), ROE quality (25 — Fortune's double standard), low leverage (15), pricing power (15), business stability (15) and capital efficiency (10), for a 0–100 total. The entry gate is the first of Berkshire's acquisition criteria — at least $50M average pre-tax earnings over the last three fiscal years (banks and insurers excluded, as leverage is their business model; investment trusts and closed-end funds excluded, as they are portfolios rather than operating companies). Recomputed periodically from each company's last ten fiscal years; cross-listings merged by canonical ticker. Hover the score for the six-dimension breakdown; companies we cover link to their report. Filtré par market "Hong Kong", profit streak "Full 10 yr", Has report : 14 match(effacer les filtres).

# Titre Mkt Cap Score Baillie 10Y ROE Profit Streak Net Debt/Eq Gross Margin Étude FY
1 Hansoh Pharmaceutical Group Co Ltd 3692 · Hong Kong $25B
94/100 Élite
53/100 26.3%low 11.4% 10 yr+ Net cash 91% Hansoh Pharmaceutical: One Molecule, One Royalty Book, and a Price That Already Pays for Both17 août 2026 · Hold FY2025
2 ANTA Sports Products Ltd 2020 · Hong Kong $28B
92/100 Élite
55/100 23.7%low 19.9% 10 yr+ Net cash 57% ANTA Sports: Other Brands Grew 59.2% While the Core Brand Managed 3.7%, and at HKD 74.50 the Shares Already Sit Above the HKD 68 Conservative Sum-of-the-Parts7 août 2026 · Hold FY2025
3 Techtronic Industries Co Ltd 0669 · Hong Kong $31B
85/100 Élite
43/100 18.7%low 17.0% 10 yr+ 0.0× 39% Techtronic Industries: MILWAUKEE Compounds Near 10% While RYOBI Barely Grows, and HK$142.40 Offers No Conservative Margin of Safety15 août 2026 · Hold FY2025
4 Tencent Holdings Ltd 0700 · Hong Kong $548B
82/100 Élite
53/100 21.1%low 13.2% 10 yr+ Net cash 48% Tencent Holdings: A 12.8% Re-Rating on an Unconfirmed WeChat Agent, While Q1 Disclosed RMB8.8 Billion of AI Drag9 août 2026 · Hold FY2025
5 Shenzhou International Group Holdings Ltd 2313 · Hong Kong $8.6B
78/100 Solide
44/100 17.2%low 12.1% 10 yr+ Net cash 28% Shenzhou International: 22.6% H1 Gross Margin and 75.9% Customer Concentration Leave No Conservative Margin of Safety at HK$36.581 septembre 2026 · Hold FY2025
6 Tingyi 0322 · Hong Kong $8.6B
77/100 Solide
33/100 18.3%low 6.8% 10 yr+ 0.1× 31% Tingyi: A Mature Cash Cow Whose Profit Growth Comes From Margin, Not Sales25 août 2026 · Hold FY2025
7 Li Ning Co Ltd 2331 · Hong Kong $4.9B
75/100 Solide
43/100 15.0%low 10.2% 10 yr+ Net cash 49% Li Ning Company: 11 Times Trailing Earnings and Almost RMB20 Billion of Net Cash, Against a Q2 2026 Sell-Through Reversal8 août 2026 · Hold FY2025
8 Chow Tai Fook Jewellery Group Ltd 1929 · Hong Kong $16B
68/100 Solide
41/100 18.2%low 9.6% 10 yr+ 0.7× 27% Chow Tai Fook Jewellery Group: A Scale Leader in Transition, Priced Around Fair Value25 juin 2026 · Hold FY2026
9 Sunny Optical Technology Group Co Ltd 2382 · Hong Kong $7.7B
68/100 Solide
47/100 22.0%low 4.9% 10 yr+ Net cash 20% Sunny Optical: Other Products Supply a Third of Gross Profit on 18.4% of Revenue, but Handset Margin at 12.3% Leaves No Safety Margin at HKD 62.6027 août 2026 · Watch FY2025
10 ENN Energy Holdings Ltd 2688 · Hong Kong $6.7B
68/100 Solide
39/100 16.5%low 12.3% 10 yr+ 0.2× 15% ENN Energy: A Lapsed HK$80 Buyout Left 7.1x Core Earnings and a 6.1% Yield, but Every Ancillary Segment Shrank in H1 and HK$49.48 Sits Above the HK$40 Ideal-Buy Ceiling16 septembre 2026 · Cautious Buy FY2025
11 Contemporary Amperex Technology Co., Limite 3750 · Hong Kong $380B
62/100 Moyen
59/100 16.7%low 8.7% 10 yr+ Net cash 29% CATL : analyse approfondie selon le Zen Horizon Framework4 juin 2026 · Achat prudent FY2025
12 WuXi AppTec Co Ltd H 2359 · Hong Kong $61B
62/100 Moyen
51/100 15.9%low 9.1% 10 yr+ Net cash 40% WuXi AppTec Co., Ltd.: Chemistry Resets the Earnings Base, the U.S. Question Stays Open, and HK$199.10 Leaves No Conservative Discount12 août 2026 · Hold FY2025
13 WuXi Biologics 2269 · Hong Kong $20B
56/100 Moyen
52/100 13.2%low 6.3% 10 yr+ Net cash 43% WuXi Biologics Deep Dive: A Biologics CRDMO Where Manufacturing Delivery Runs Ahead While Valuation Is Held Back by a Geopolitical Discount12 juin 2026 · Hold FY2025
14 WuXi XDC Cayman Inc 2268 · Hong Kong $8.8B
48/100 Faible
48/100 17.4%low 5.2% 10 yr+ Net cash 30% WuXi XDC : industrialiser le réseau de fabrication d'ADC17 juin 2026 · Conserver FY2025

Data and methodology: the six dimensions quantify Berkshire's published acquisition criteria and Buffett's shareholder letters (1981/1987/1991/2007 among others). Qualitative tests in the originals (e.g. "simple, understandable business", "management in place") are out of scope, and price ("available at a fair price") is covered by each report's valuation range instead. Financials come from company annual reports (via EODHD); ratios are computed in reporting currency, the USD gate via static FX. "‡" marks companies whose equity is persistently negative or tiny (ROE falls back to ROCE); "†" marks missing gross profit (operating margin used). Investment trusts and closed-end funds are excluded on two tests — name and financial shape (operating margins beyond what an operating company can achieve); REITs and operating asset managers are unaffected. This is a quantitative first pass, not investment advice. When citing this data, please credit Zen Horizon (zh.app). See our methodology for the scoring process.